Data on Tumor Treating Fields to be Presented at the 37th Annual Conference of the IEEE Engineering in Medicine and Biology Society

St. Helier, Jersey – August 26, 2015 – Novocure, a commercial stage oncology company, announced today that data describing the latest understanding of how Tumor Treating Fields (TTFields) distribute within tissues and cells will be presented at the 37th Annual International Conference of the Institute of Electrical and Electronics Engineers (IEEE) Engineering in Medicine and Biology Society in Milan, Italy from August 25 to August 29, 2015. The oral and poster presentations will be the first time data on TTFields are presented at a conference sponsored by the Institute of Electrical and Electronics Engineering (IEEE). IEEE is the world’s largest professional association dedicated to the advancement of technology with over 426,000 members in more than 160 countries.

“We are thrilled to have the opportunity to present data at such an important conference as IEEE and are especially proud that Dr. Wenger was given an oral presentation for her work modelling TTFields,” said Eilon Kirson, MD, PhD, Novocure’s Chief Science Officer. “We believe that these presentations are critical in raising awareness of Novocure’s novel technology within the engineering and broader scientific community.”

Data presentations include those listed below:

**Modelling Tumor Treating Fields Application within a Realistic Human Head Model**
Presenter: Cornelia Wenger, PhD, Institute of Biophysics and Biomedical Engineering, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal
Date and Time: Thursday, August 27, 2015, 8:30 to 8:45 AM (oral presentation)
Abstract Identifier: ThAT15.1
Room: White 1

**Modelling Tumor Treating Fields Application in Single Cells during Metaphase and Anaphase**
Presenter: Cornelia Wenger, PhD, Institute of Biophysics and Biomedical Engineering, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal
Date and Time: Friday, August 28, 2015, 10:00 to 11:30 AM (poster presentation)
Abstract Identifier: FrBPot23.2
Room: Gold Room

**About IEEE**
IEEE is the world’s largest professional association dedicated to the advancement of technology with over 426,000 members in more than 160 countries. IEEE members are engineers, scientists, and allied professionals whose technical interests are rooted in electrical and computer sciences, engineering, and related disciplines. IEEE Engineering in Medicine and Biology Society (EMBS) is the world’s largest international society of biomedical engineers.

**About Tumor Treating Fields Therapy**
Tumor Treating Fields (TTFields) therapy is delivered by a portable, non-invasive medical device designed for continuous use by patients. *In vitro* and *in vivo* studies have shown that TTFields therapy slows and reverses tumor growth by inhibiting mitosis, the process by which cells divide and replicate. TTFields therapy creates low intensity, alternating electric fields within a tumor that exert physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death.

**Approved Indications**
The US FDA has approved the TTFields therapy delivery system, Optune (previously known as the NovoTTF-100A System), for use as a treatment for adult patients (22 years of age or older) with histologically-confirmed GBM, following histologically or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy. The device is intended to be used as
monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted. Patients should only use Optune under the supervision of a physician properly trained in use of the device. Full prescribing information is available at www.optune.com/safety or by calling toll free 1-855-281-9301.

In the European Union, Optune is intended for the treatment of patients with newly diagnosed GBM, after surgery and radiotherapy with adjuvant temozolomide, concomitant to maintenance temozolomide. The treatment is intended for adult patients, 18 years of age or older, and should be started more than 4 weeks after surgery and radiation therapy with adjuvant temozolomide. Treatment may be given together with maintenance temozolomide and after maintenance temozolomide is stopped.

In the European Union, Optune is also intended for the treatment of patients with recurrent GBM who have progressed after surgery, radiotherapy and temozolomide treatment for their primary disease. The treatment is intended for adult patients, 18 years of age or older, and should be started more than 4 weeks after the latest surgery, radiation therapy or chemotherapy.

**About Novocure**

Novocure is a private Jersey Isle oncology company pioneering a novel therapy for solid tumors called TTFields. Novocure’s US operations are based in Portsmouth, NH and New York, NY. Additionally, the company has offices in Switzerland and Japan and a research center in Haifa, Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.

###

**Media and Investor Contact:**

Ashley Cordova, Novocure
acordova@novocure.com
(212) 767-7558